Critical Limb Ischemia Clinical Trial
Official title:
An Open Labeled, Single-center, Phase I Study Assessing the Safety and Efficacy of Autologous Bone Marrow Derived Mesenchymal Stem Cells in Critical Limb Ischemia
Verified date | March 2019 |
Source | Pharmicell Co., Ltd. |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This clinical trial to study the Safety and Efficacy of Autologous Mesenchymal stem cells in critical limb ischemia.
Status | Withdrawn |
Enrollment | 0 |
Est. completion date | June 2020 |
Est. primary completion date | June 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility |
Inclusion Criteria: - Age from 20 to 80 years - Patients with resting pain or ulceration of limb (Rutherford's class: II-4, III-5 or III-6) - Ankle Brachial Pressure Index (ABPI) = 0.6 or TCPO2 = 60mmHg in the foot - Patients who were unsuitability for percutaneous transluminal angioplasty or a bypass operation - Patients who are not expected other treatments for at least 6 months - Patients who can agree to participate in the clinical trial by oneself or by one's legal representative - Patients who can conduct the clinical trial according to the protocol Exclusion Criteria: - Buerger's disease - History of hematologic disease - Patients who are at risk of embolism due to atrial fibrillation - Primary hematologic disease, including hypercoagulable states - Entrapment syndrome - Patients with osteomyelitis - Patients whose blood serum AST(Aspartate transaminase)/ALT(Alanine Transaminase) rates are more than three times the normal maximum rate, or whose creatinine rates are more than 1.5 times the normal maximum rate - Patients with history of anaphylaxis to gentamicin - Patients with hypersensitivity of bovine-derived ingredients - Patients with chronic heart failure, Glomerular disease and Obstructive pulmonary disease - Patients with Stroke or transient ischemic attack within 6 months prior to registration - Patients tested positive for HIV(Human Immunodeficiency Virus), HCV(Hepatitis C Virus), HBV(Hepatitis B Virus) and Syphilis - Patients with history of aorta and artery bypass operation, or angioplasty within 2 months recently - Patients in need of a immediate amputation and have a potentially life-threatening complications of critical ischemia - Patients with history of cell therapy - Type I diabetes - Uncontrolled diabetes mellitus (HgbA1C>8%) - Uncontrolled hypertension - Has a medical record of solid cancer, or diagnosed with solid cancer and currently receiving cancer treatment - Positive of tumor markers test(AFP((Alpha fetoprotein), CEA(Carcinoembryonic antigen), CA15-3(Cancer antigen 15-3 for breast cancer) and PSA(Prostate-specific antigen), or have received a diagnosis of cancer based on National cancer screening program - Pregnancy, possible candidate for pregnancy or lactating women - Infectious disease - Administrating of immunosuppressive agents, corticosteroid formulation and cell toxicity formulation, or requiring administration of the test period - Patients already enrolled in another clinical trials or completed within 3 months - Patients who cannot adapt to the protocol and follow-up observation - Patients who has experienced drug abuse for the past 1 year - Patients with any disease or condition which the investigator fell would interfere with trial or the safety of the subject |
Country | Name | City | State |
---|---|---|---|
n/a |
Lead Sponsor | Collaborator |
---|---|
Pharmicell Co., Ltd. |
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | For safety analysis we will observed clinical laboratory tests, physical examinations, tumor marker tests | Analyze using McNemar's test by making a table of changes that occurred in the test. clinical laboratory tests(Follow the unit of each institution): physical examinations: -Allergy, Cardiovascular, Respiratory, Gastrointestinal /Liver biliary, Metabolic / endocrine, Kidney / urinary system, Reproductive, Musculoskeletal, Skin and connective, Nervous, Psyatric, Others tumor marker tests(Follow the unit of each institution): AFP CEA CA15-3(female) PSA(male) |
12 months after BM-MSC therapy | |
Other | occurrence and severity of adverse events | Analyze the adverse events by using seriousness, severity and relevance of IP. | 12 months after BM-MSC therapy | |
Primary | Ankle Brachial Pressure Index, ABPI | Use Student's paired t-test or Wilcoxon's signed rank test to compare the difference of between the two visits(Screening and 6 month post treatment) before and after treatment. | 6 months after BM-MSC therapy | |
Secondary | Collateral vessel formation on digital subtraction angiography (DSA) | Analyze the difference of pre and post treatment using McNemar test for homogeneity test. | 6 months after BM-MSC therapy | |
Secondary | Difference of Wound size | Use Student's paired t-test or Wilcoxon's signed rank test to compare the difference of pre and post treatment Healing of ulcerations (change in size of ulcers) or reduction of ulcer area in the target limb. | 6 months after BM-MSC therapy | |
Secondary | Improved transcutaneous oxygen pressure (TCPO2) | Use Student's paired t-test or Wilcoxon's signed rank test to compare the difference of pre and post treatment transcutaneous oxygen pressure (TCPO2). | 6 months after BM-MSC therapy | |
Secondary | Pain on the Visual Analogue Scale(VAS) | Use Student's paired t-test or Wilcoxon's signed rank test to compare the difference of pre and post Visual Analogue Scale(VAS). Visual Analogue Scale(VAS): Using a ruler, the score is determined by mea-suring the distance (mm) on the 10-cm line between the "no pain" anchor and the patient's mark, providing a range of scores from 0-100. A higher score indicates greater pain intensity. the following cut points on the pain VAS have been recommended: no pain (0-4 mm), mild pain(5-44 mm), moderate pain (45-74 mm), and severe pain (75-100 mm) |
6 months after BM-MSC therapy | |
Secondary | Reduced limb amputation | Described and define as minor amputation is below midtarsal level, major amputation is more than midtarsal level. | 6 months after BM-MSC therapy | |
Secondary | Temperature change on thermography | Use Student's paired t-test or Wilcoxon's signed rank test to compare the difference of pre and post thermography. | 6 months after BM-MSC therapy | |
Secondary | Dose about using analgesic medicine | Use Student's paired t-test or Wilcoxon's signed rank test to compare the difference between pre and post dose of the using analgesic medicine. | 6 months after BM-MSC therapy | |
Secondary | Change in Rutherford classification | Use Student's paired t-test or Wilcoxon's signed rank test to compare the difference of pre and post Rutherford classification. Rutherford classification: commonly used clinical staging system for describing peripheral arterial disease. Stage 0 - Asymptomatic Stage 1 - Mild claudication Stage 2 - Moderate claudication - The distance that delineates mild, moderate and severe claudication is not specified in the Rutherford classification, but is mentioned in the Fontaine classification as 200 meters. Stage 3 - Severe claudication Stage 4 - Rest pain Stage 5 - Ischemic ulceration not exceeding ulcer of the digits of the foot Stage 6 - Severe ischemic ulcers or frank gangrene |
6 months after BM-MSC therapy | |
Secondary | Frequency about using analgesic medicine | Use Student's paired t-test or Wilcoxon's signed rank test to compare the difference between pre and post frequency of the using analgesic medicine. | 6 months after BM-MSC therapy |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT03987061 -
MOTIV Bioresorbable Scaffold in BTK Artery Disease
|
N/A | |
Recruiting |
NCT03668353 -
Recombinant SeV-hFGF2/dF Injection for PAOD
|
Phase 1 | |
Recruiting |
NCT04110964 -
Evaluation of Safety and Tolerability of Libella Gene Therapy for Critical Limb Ischemia: AAV- hTERT
|
Phase 1 | |
Not yet recruiting |
NCT03994666 -
Cell Therapy in Critical Limb Ischemia
|
Phase 2 | |
Recruiting |
NCT02389023 -
Comparison of Prevena Negative Pressure Incision Management System vs. Standard Dressing After Vascular Surgery
|
N/A | |
Not yet recruiting |
NCT02498080 -
Drug Eluting Balloons PTA in Infra-popliteal Arteries in Patients With Critical Limb Ischemia
|
N/A | |
Completed |
NCT02539940 -
Elutax-SV Drug-eluting Balloons for Below-the-knee Treatment
|
||
Recruiting |
NCT02239419 -
Evaluation of Carbothera in the Treatment of Foot Ulcers
|
N/A | |
Recruiting |
NCT01938872 -
Evaluating the Effectiveness of Paclitaxel-eluting Balloons for Below-the-knee Angioplasty in Patients With Critical Limb Ischemia
|
N/A | |
Active, not recruiting |
NCT01211925 -
Distal Venous Arterialisation of Ischemic Limb
|
Phase 2/Phase 3 | |
Completed |
NCT02454231 -
Monocentric Trial: Stem Cell Emergency Life Threatening Limbs Arteriopathy (SCELTA)
|
Phase 2/Phase 3 | |
Completed |
NCT01758874 -
Study to Explore the Effect of Lowering Blood Viscosity in Patients With Treatment-resistant Critical Limb Ischemia
|
Phase 2 | |
Completed |
NCT02475200 -
Phoenix Post-Approval Registry - Using the Phoenix Atherectomy Systems
|
||
Recruiting |
NCT04583436 -
Efficacy and Safety Comparison of the Open and Endovascular Surgical Methods for the Treatment of Long Atherosclerotic Lesions of the Femoral-popliteal Segment Below the Knee, TASC D in Patients With Critical Limb Ischemia
|
N/A | |
Completed |
NCT04071782 -
Investigating the Safety and Efficacy of the Treatment With the Selution Sirolimus Coated Balloon in TASC C and D Tibial Occlusive Disease in Patients With Critical Limb Ischemia From Singapore
|
N/A | |
Completed |
NCT03669458 -
Feasibility Clinical Trial Using the SPUR System to Demonstrate Safety and Efficacy.
|
N/A | |
Not yet recruiting |
NCT06007469 -
Pedal Acceleration Time (PAT) as a Measure of Foot Perfusion
|
||
Recruiting |
NCT04110327 -
An All-Comers Observational Study of the MicroStentâ„¢ Peripheral Vascular Stent System in Subjects With Peripheral Arterial Disease
|
||
Completed |
NCT02260622 -
Pilot Study to Examine the Use of Rivaroxaban After Angioplasty for Critical Limb Ischemia
|
Phase 2 | |
Recruiting |
NCT02054416 -
External Compression Therapy for Secondary Prevention of Lower-Limb Loss and Cardiovascular Mortality
|
N/A |